News 2023

Kung-Yee Liang, PH.D. was elected as the chairman of OBI Pharma, Inc.

OBI Pharma, Inc. (4174.TWO) held a board meeting today (29th) and unanimously elected Kung-Yee Liang PH.D., the new legal representative, former president of the National Health Research Institutes (NHRI), and …

OBI Pharma proprietary ADC technology platform “plug and play”

site-specific conjugation, scalable manufacturing process, and suitability for various antibodies, linkers, or payload, establish a straightforward and efficient process in the development of ADC Antibody Drug Conjugate (ADC) has emerged …

OBI Achieves ISO/IEC 27001 International Information Security Certification

After two years of continuous effort, OBI has successfully established an Information Security Management System and recently obtained ISO/IEC 27001 certification. SGS Group, responsible for the verification, specially designated Mr. …

OBI VOLUNTEERS ON A MISSION!

▲ OBI Volunteers Team.  Photo / Provided by TBCA In Pink Oct , WHO designates it as ‘International Breast Cancer Awareness Month’ and calls for various activities worldwide to express …

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. appointed as Chief Executive Officer

Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision to bring innovative cancer therapies to patients globally. She …

Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

Title: OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab Abstract number: 5946 / Poster number: 5946/7 Title: Globo H-targeted CAR T cell cancer …

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

Poster Presentations to highlight the latest research on OBI-999’s (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and OBI’s development of CAR T-cell cancer immunotherapy targeting Globo H. …